Enanta Q3 Revenue Falls to $14.4 Million; Net Loss Widens to $19.5 Million
Enanta Pharmaceuticals reported results for its fiscal third quarter ended June 30, 2026. Revenue fell to $14.4 million from $18.3 million a year earlier, mainly on lower AbbVie HCV sales, and the net loss widened to $19.5 million from $18.3 million, although the per-share loss narrowed to $0.67 from $0.85 on a higher share count.
Key points
- Revenue was $14.4 million versus $18.3 million a year earlier, reflecting lower reported AbbVie HCV sales of MAVYRET/MAVIRET.
- Net loss was $19.5 million, or $0.67 per diluted share, versus a net loss of $18.3 million, or $0.85 per diluted share, a year earlier.
- Cash, cash equivalents and marketable securities totaled $211.5 million at June 30, 2026; the company expects funds to last into fiscal 2029.
- RESOLVE, a registrational Phase 2b/3 trial of zelicapavir, is on track to start in the fourth quarter of 2026.
The filing
Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 10, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.